Details for Patent: 8,324,189

Which drugs does patent 8,324,189 protect, and when does it expire?

Patent 8,324,189 protects ZOMETA and is included in one NDA.

Protection for ZOMETA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirteen patent family members in nine countries.

Summary for Patent: 8,324,189

Patent landscape, scope, and claims:

Title:	Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
Abstract:	A method of intravenously administering a bisphosphonate to a patient in need of bisphosphonate treatment comprising intravenously administering 4 mg of 2-(imidazol-1yl)-1-hydroxyethane-1,1-diphosphonic acid (zoledronic acid) or a pharmaceutically acceptable salt thereof over a period of 15 minutes to a patient in need of said treatment.
Inventor(s):	Galli; Bruno (Seltisberg, CH), Schran; Horst F (Morristown, NJ), Seaman; John J (New Hope, PA)
Assignee:	Novartis Pharmaceuticals Corporation (East Hanover, NJ)
Application Number:	11/594,410
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,324,189
Patent Claim Types: see list of patent claims	Use; Formulation;

Drugs Protected by US Patent 8,324,189

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis	ZOMETA	zoledronic acid	INJECTABLE;INTRAVENOUS	021223-002	Mar 7, 2003		DISCN	Yes	No	8,324,189*PED				Y
Novartis	ZOMETA	zoledronic acid	INJECTABLE;INTRAVENOUS	021223-003	Jun 17, 2011		DISCN	Yes	No	8,324,189*PED				Y

International Family Members for US Patent 8,324,189

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2001261283
Australia	6128301
Brazil	0110913